Why Is BillionToOne (BLLN) Stock Down -39.01% Today?
Key Takeaways
- BillionToOne shares plunged approximately 39% on Thursday, erasing months of gains in a single session following its Q2 2026 earnings report.
- The primary catalyst was the company's decision to reiterate full-year revenue guidance of $450–$465 million rather than raising it, despite beating earnings and revenue expectations across the board.
- The stock had rallied roughly 84% since its Q1 beat-and-raise in early May, leaving it priced for perfection near its 52-week high of $150.44 heading into the report.
- Several Wall Street analysts cut price targets, including JPMorgan (to $130 from $145) and BTIG (to $130 from $142), though both maintained bullish ratings.
- The sell-off spread across the medical diagnostics sector, with Grail (GRAL) falling over 12%, though Caris Life Sciences (CAI) bucked the trend on strong results and raised guidance.
- Traders are now watching upcoming product launches — including Unity expanded fetal risk screening on August 17 and Northstar Origin on September 1 — for the next potential catalyst.
Opening Summary
BillionToOne, Inc. (BLLN), a Menlo Park-based molecular diagnostics company specializing in non-invasive prenatal testing and oncology liquid biopsies, saw its stock crater by roughly 39% in Thursday's session. Shares that closed Wednesday at $149.97 — just pennies below the company's all-time high — tumbled to approximately $91.46 intraday, wiping out over $2.6 billion in market capitalization. The brutal sell-off came despite a second-quarter earnings report that featured 64% year-over-year revenue growth to $109.4 million, gross margins of 70%, and GAAP net income of $8.1 million, or $0.15 per diluted share. The culprit: management held its full-year 2026 revenue outlook steady at $450–$465 million, dashing hopes that the scorching growth trajectory would translate into yet another guidance raise.
Earnings Beat Everything Except Expectations
By virtually every conventional metric, BillionToOne delivered an outstanding quarter. Revenue of $109.4 million topped the consensus estimate of approximately $108.8 million. Prenatal clinical testing revenue surged 55% to $94.2 million, while oncology clinical testing revenue exploded 176% to $13.7 million. The company processed 196,000 tests during the quarter, up 35% year-over-year, with an average selling price of $551 — up 21% from the prior year. Gross margins expanded five percentage points to 70%, and BillionToOne generated $5.1 million in free cash flow while ending the quarter with $549 million in cash and equivalents. The company also achieved GAAP operating income of $5.5 million, a dramatic reversal from the $1.6 million operating loss posted in the same period last year.
Yet the market's reaction was ruthless. The problem was not the numbers themselves but the context in which they arrived. Since reporting first-quarter results on May 6 — a report that included both a top-and-bottom-line beat and an upward guidance revision — BLLN stock had soared more than 84%. By Wednesday's close at $149.97, the shares sat just $0.47 below their 52-week high of $150.44, reflecting sky-high investor expectations. As William Blair analyst Matt Larew noted, the company became "a victim of its own success." The market had priced in a guidance raise alongside strong results, and when the raise failed to materialize, the air came out of the stock in dramatic fashion.
Guidance Reiteration Sparks the Sell-Off
Management's decision to stand pat on its 2026 revenue forecast of $450 million to $465 million — representing 48% to 52% growth over 2025 — proved to be the tripwire. BillionToOne has a track record of consistently exceeding its own projections. In 2023, it delivered $72 million against a $65 million forecast. In 2024, revenue hit $153 million versus a projected $125 million. In 2025, the company generated $305 million against $220 million in guidance. That history of under-promising and over-delivering conditioned investors to expect a raise as routine, particularly after a quarter with 64% revenue growth.
During the earnings call, management indicated the quarter was "very much in line with its internal expectations" and expressed confidence in the building blocks for 2027. The company also highlighted upcoming commercial launches — an expanded Unity fetal risk screening product on August 17 and Northstar Origin on September 1 — but these forward-looking catalysts were not enough to satisfy traders who had bid the stock up relentlessly for three months.
Analyst Price Targets Trimmed
In the wake of the report, at least two major Wall Street firms lowered their price targets on BLLN. JPMorgan analyst Casey Woodring cut the target to $130 from $145 while maintaining an Overweight rating, describing the quarter as "a bit of an underwhelming" result with in-line revenue and volume growth. BTIG's Mark Massaro similarly reduced his target to $130 from $142, keeping a Buy rating and characterizing the sell-off as an attractive buying opportunity given the company's leading technology platform, financial profile, and upcoming catalysts. Importantly, no analyst downgraded their rating — the consensus remained Buy across the Street — but the magnitude of the post-earnings decline underscored just how elevated the pre-report expectations had become.
Market Context and Trading Activity
Volume in BLLN surged to multiple times the daily average, with over 2.7 million shares changing hands by mid-afternoon compared to an average daily volume of roughly 755,000. The sell-off was not confined to BillionToOne alone. The medical diagnostics and research sector came under broad pressure, with cancer screening company GRAL (Grail) slumping more than 12% after announcing that the FDA would hold an advisory committee meeting to evaluate its Galleri blood test. Investor's Business Daily's Medical-Research industry group slid more than 1% on the day.
However, the pain was not uniform. CAI (Caris Life Sciences) rallied over 16% after it beat June-quarter expectations and raised its full-year guidance — offering a stark contrast to BillionToOne's unchanging outlook and underscoring the market's laser focus on forward guidance over backward-looking results.
From a technical perspective, BLLN shares sliced decisively below both the 21-day and 50-day moving averages, levels that had provided support throughout the stock's multi-month advance. The breach of these widely watched technical indicators likely triggered additional algorithmic and momentum-driven selling, compounding the fundamental disappointment.
What Comes Next for BLLN
The near-term narrative for BillionToOne now hinges on execution of its upcoming product launches. The expanded Unity fetal risk screening product, set for commercial launch on August 17, and Northstar Origin, a tumor-naive minimal residual disease test expected on September 1, represent the next wave of growth catalysts. The company is also progressing toward MolDX coverage for its Northstar Response therapy monitoring assay, which could meaningfully expand the oncology revenue opportunity.
Management has indicated that the company expects to remain GAAP profitable while continuing significant investments in commercial expansion and research. With $549 million in cash, BillionToOne has ample runway to fund its growth ambitions. However, the stock's violent repricing raises legitimate questions about whether its premium valuation — even after the sell-off — can be sustained if revenue growth decelerates or if competitive pressures from rivals such as Natera intensify in the prenatal testing market.
Upcoming milestones include any updates on payer coverage expansion, FDA regulatory developments, and the early commercial traction of the newly launched products. For a stock that doubled on a beat-and-raise cycle, the reset in expectations following an in-line quarter may take more than one session to fully digest.
Trending AI Robots
Tickeron's Trending AI Robots page features a curated selection of AI-powered trading bots that have demonstrated strong performance under current market conditions. With hundreds of bots covering thousands of tickers — including stocks like BLLN — Tickeron's platform spans diverse strategies, timeframes, and performance metrics. Only the bots that are currently outperforming make it into the Trending AI Robots section, giving traders a real-time window into which algorithmic strategies are navigating market volatility most effectively. Explore the Trending AI Robots to discover which AI-driven approaches are gaining traction right now.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
BLLN's RSI Indicator reaching into overbought territory
The RSI Oscillator for BLLN moved into overbought territory on August 05, 2026. Be on the watch for a price drop or consolidation in the future -- when this happens, think about selling the stock or exploring put options.
Technical Analysis (Indicators)
Bearish Trend Analysis
The Stochastic Oscillator demonstrated that the ticker has stayed in the overbought zone for 5 days. The longer the ticker stays in the overbought zone, the sooner a price pull-back is expected.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where BLLN declined for three days, the price rose further in of 62 cases within the following month. The odds of a continued downward trend are .
BLLN broke above its upper Bollinger Band on August 05, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
Bullish Trend Analysis
The Momentum Indicator moved above the 0 level on July 27, 2026. You may want to consider a long position or call options on BLLN as a result. In of 14 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are .
The Moving Average Convergence Divergence (MACD) for BLLN just turned positive on July 31, 2026. Looking at past instances where BLLN's MACD turned positive, the stock continued to rise in of 8 cases over the following month. The odds of a continued upward trend are .
Following a 3-day Advance, the price is estimated to grow further. Considering data from situations where BLLN advanced for three days, in of 42 cases, the price rose further within the following month. The odds of a continued upward trend are .
The Aroon Indicator entered an Uptrend today. In of 17 cases where BLLN Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are .
Fundamental Analysis (Ratings)
The Tickeron Price Growth Rating for this company is (best 1 - 100 worst), indicating steady price growth. BLLN’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Valuation Rating of (best 1 - 100 worst) indicates that the company is slightly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (13.643) is normal, around the industry mean (59.121). P/E Ratio (277.176) is within average values for comparable stocks, (162.532). BLLN's Projected Growth (PEG Ratio) (0.000) is slightly lower than the industry average of (1.678). BLLN has a moderately low Dividend Yield (0.000) as compared to the industry average of (0.007). P/S Ratio (19.455) is also within normal values, averaging (8.699).
The Tickeron SMR rating for this company is (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron PE Growth Rating for this company is (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Profit vs. Risk Rating rating for this company is (best 1 - 100 worst), indicating that the returns do not compensate for the risks. BLLN’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 92, placing this stock worse than average.
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement
Advertisement